[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20131324A1 - Formulacion subcutanea de anticuerpo anti-her2 - Google Patents

Formulacion subcutanea de anticuerpo anti-her2

Info

Publication number
PE20131324A1
PE20131324A1 PE2013000301A PE2013000301A PE20131324A1 PE 20131324 A1 PE20131324 A1 PE 20131324A1 PE 2013000301 A PE2013000301 A PE 2013000301A PE 2013000301 A PE2013000301 A PE 2013000301A PE 20131324 A1 PE20131324 A1 PE 20131324A1
Authority
PE
Peru
Prior art keywords
her2 antibody
subcutaneous formulation
formulation
subcutaneous
lacks
Prior art date
Application number
PE2013000301A
Other languages
English (en)
Inventor
Michael Adler
Ulla Grauschopf
Hanns-Christian Mahler
Oliver Boris Stauch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43500473&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131324(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20131324A1 publication Critical patent/PE20131324A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA FORMULACION FARMACEUTICA DE UN ANTICUERPO ANTI-HER2 ALTAMENTE CONCENTRADA Y ESTABLE, PARA ADMINISTRACION SUBCUTANEA Y QUE CONTIENE: A) ENTRE 50 Y 350 MG/ML DEL ANTICUERPO ANTI-HER2; B) ENTRE 1 Y 100 mM DE UN AGENTE TAMPONADOR QUE PROPORCIONA UN PH DE 5,5; C) ENTRE 1 Y 500 mM DE UN ESTABILIZANTE O UNA MEZCLA DE DOS O MAS ESTABILIZANTES; Y D) ENTRE 0,01 Y 0,1% DE UN TENSIOACTIVO NO IONICO. DICHA FORMULACION ES UTIL EN EL TRATAMIENTO DE CANCER Y CARECE DE LA ENZIMA HIALURONIDASA
PE2013000301A 2009-07-31 2010-07-28 Formulacion subcutanea de anticuerpo anti-her2 PE20131324A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09167025 2009-07-31

Publications (1)

Publication Number Publication Date
PE20131324A1 true PE20131324A1 (es) 2013-11-04

Family

ID=43500473

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2013000301A PE20131324A1 (es) 2009-07-31 2010-07-28 Formulacion subcutanea de anticuerpo anti-her2
PE2012000105A PE20120665A1 (es) 2009-07-31 2010-07-28 Formulacion subcutanea de anticuerpo anti-her2

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2012000105A PE20120665A1 (es) 2009-07-31 2010-07-28 Formulacion subcutanea de anticuerpo anti-her2

Country Status (41)

Country Link
US (6) US9345661B2 (es)
EP (4) EP2687202B1 (es)
JP (2) JP5462944B2 (es)
KR (2) KR101413947B1 (es)
CN (3) CN113967194A (es)
AR (2) AR077605A1 (es)
AU (1) AU2010277657B2 (es)
BR (1) BR112012002080A2 (es)
CA (1) CA2768458C (es)
CL (2) CL2012000269A1 (es)
CO (1) CO6430421A2 (es)
CR (1) CR20110679A (es)
CY (1) CY1114185T1 (es)
DK (2) DK2687202T3 (es)
DO (1) DOP2015000255A (es)
EA (2) EA027553B1 (es)
EC (2) ECSP12011643A (es)
ES (2) ES2413090T5 (es)
FI (1) FI2687202T3 (es)
GT (1) GT201200024A (es)
HK (2) HK1172236A1 (es)
HR (2) HRP20130697T4 (es)
HU (1) HUE062122T2 (es)
IL (2) IL217382A (es)
IN (1) IN2012CN00961A (es)
LT (1) LT2687202T (es)
MA (1) MA33471B1 (es)
MX (2) MX2012001124A (es)
MY (2) MY163001A (es)
NZ (2) NZ603900A (es)
PE (2) PE20131324A1 (es)
PL (2) PL2459167T5 (es)
PT (2) PT2687202T (es)
RS (2) RS64314B1 (es)
SG (2) SG193146A1 (es)
SI (2) SI2459167T2 (es)
TN (1) TN2012000023A1 (es)
TW (2) TWI401089B (es)
UA (2) UA102166C2 (es)
WO (1) WO2011012637A2 (es)
ZA (2) ZA201109459B (es)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PL1850874T3 (pl) 2005-02-23 2014-03-31 Genentech Inc Wydłużanie czasu do progresji choroby lub przeżycia u chorych na raka jajnika stosujących pertuzumab
PE20090681A1 (es) 2007-03-02 2009-06-10 Genentech Inc Prediccion de respuesta a un inhibidor her
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
JP5540095B2 (ja) * 2009-07-24 2014-07-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗体製造の最適化
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
RU2012131099A (ru) * 2009-12-29 2014-02-10 Ф. Хоффманн-Ля Рош Аг Препарат антитела
US9220776B2 (en) 2011-03-31 2015-12-29 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
AU2012322797B2 (en) 2011-10-14 2016-04-21 Genentech, Inc. Uses for and article of manufacture including HER2 dimerization inhibitor Pertuzumab
CN104080811B (zh) 2011-11-04 2019-09-27 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
AR090244A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Formulacion de anticuerpo anti-selectina p
WO2013173789A2 (en) * 2012-05-17 2013-11-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
ES2682761T3 (es) 2012-05-18 2018-09-21 Genentech, Inc. Formulaciones de anticuerpos monoclonales de alta concentración
ES2704487T3 (es) 2012-06-21 2019-03-18 Synthon Biopharmaceuticals Bv Método de purificación de un anticuerpo
WO2014052713A2 (en) 2012-09-27 2014-04-03 Massachusetts Institute Of Technology Her2-and vegf-a-binding proteins with enhanced stability
KR101454646B1 (ko) * 2012-11-05 2014-10-27 (주)한국비엠아이 히알루로니다아제의 안정화 제제 및 이를 포함하는 액상제제
BR112015014853A2 (pt) * 2012-12-21 2017-08-22 Glenmark Pharmaceuticals Sa Formulação farmacêutica, formulação farmacêutica liofilizada, uso de uma formulação farmacêutica e artigo de manufatura
JP6511609B2 (ja) * 2013-03-13 2019-05-22 ジェネンテック， インコーポレイテッド 抗体製剤
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
TWI554284B (zh) 2013-04-16 2016-10-21 建南德克公司 帕妥珠單抗（ｐｅｒｔｕｚｕｍａｂ）變體及其評估
SI3043774T1 (sl) * 2013-09-11 2021-01-29 Eagle Biologics, Inc. Tekoče proteinske formulacije, ki vsebujejo ionske tekočine
HUE052506T2 (hu) * 2014-02-28 2021-05-28 Merus Nv Antitest, amely megköti az ERBB-2-t és az ERBB-3-at
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
CN104906576B (zh) * 2014-03-13 2018-06-19 四川科伦博泰生物医药股份有限公司 可供皮下注射的高浓度抗vegf抗体配制剂
SG11201608912VA (en) 2014-04-25 2016-11-29 Genentech Inc Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
CN106573955B (zh) 2014-06-23 2021-02-26 诺华股份有限公司 位点特异性蛋白质修饰
US20170204149A1 (en) 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
AU2015318001B2 (en) 2014-09-15 2021-03-25 Genentech, Inc. Antibody formulations
JP2018507187A (ja) 2015-01-23 2018-03-15 ノバルティス アーゲー 改善された半減期を有する合成アペリン脂肪酸コンジュゲート
US9824394B1 (en) 2015-02-06 2017-11-21 Square, Inc. Payment processor financing of customer purchases
US9779432B1 (en) 2015-03-31 2017-10-03 Square, Inc. Invoice financing and repayment
EP4219561A3 (en) 2015-05-20 2023-11-08 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
LT3302551T (lt) 2015-05-30 2024-09-10 F. Hoffmann-La Roche Ag Anksčiau negydyto metastazavusio her2 teigiamo krūties vėžio gydymo būdai
CN107708734B (zh) * 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
KR20170004814A (ko) * 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
WO2017003270A1 (ko) * 2015-07-02 2017-01-05 주식회사 녹십자 헌터증후군 치료제 및 치료방법
CA2999079A1 (en) * 2015-09-28 2017-04-06 Jiangsu Hengrui Medicine Co., Ltd. Stable anti-pd-1 antibody pharmaceutical preparation and application thereof in medicine
CN115925944A (zh) 2015-10-23 2023-04-07 美勒斯公司 抑制癌症生长的结合分子
SI3827845T1 (sl) 2015-11-03 2022-06-30 Janssen Biotech, Inc. Subkutane formulacije protiteles proti CD38 in njihove uporabe
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
US20190000923A1 (en) 2015-12-22 2019-01-03 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
JP7082070B2 (ja) 2016-06-30 2022-06-07 セルトリオン・インコーポレイテッド 安定な液体医薬製剤
AU2017327723B2 (en) 2016-09-14 2022-11-17 Teneobio, Inc. CD3 binding antibodies
US11400109B2 (en) * 2016-11-10 2022-08-02 Translate Bio, Inc. Subcutaneous delivery of messenger RNA
IL267485B2 (en) 2016-12-21 2024-01-01 Teneobio Inc Antibodies against BCMA containing only heavy chains and their uses
WO2018125589A1 (en) 2016-12-28 2018-07-05 Genentech, Inc. Treatment of advanced her2 expressing cancer
EP3868404A1 (en) * 2017-01-17 2021-08-25 F. Hoffmann-La Roche AG Subcutaneous her2 antibody formulations
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
MX2019011660A (es) 2017-03-31 2019-11-18 Merus Nv Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
JP2020517273A (ja) 2017-04-24 2020-06-18 ジェネンテック， インコーポレイテッド 膜貫通ドメインまたは膜近傍ドメインにおけるＥｒｂＢ２／Ｈｅｒ２突然変異
CA3060581A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
SG11202003754YA (en) 2017-05-16 2020-05-28 Bhamis Research Laboratory Pvt Ltd High concentration protein formulations with reduced viscosity
CN110506058A (zh) * 2017-06-02 2019-11-26 豪夫迈·罗氏有限公司 免疫激动剂的施用路径
KR20200018498A (ko) 2017-06-20 2020-02-19 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
JP7240335B2 (ja) 2017-06-20 2023-03-15 テネオワン， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
CA3068167A1 (en) 2017-06-23 2018-12-27 Anette Weyergang Diagnosis and treatment of cancer
AU2018308930A1 (en) * 2017-07-28 2020-02-06 F. Hoffmann-La Roche Ag Bispecific antibody formulation
JP2020530028A (ja) 2017-08-09 2020-10-15 メルス ナムローゼ フェンノートシャップ ＥＧＦＲ及びｃＭＥＴに結合する抗体
AU2018331421A1 (en) 2017-09-13 2020-04-30 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
MX2020002896A (es) * 2017-09-15 2020-07-22 Amgen Inc Proceso para formulacion farmaceutica liofilizada de una proteina terapeutica.
WO2019089832A1 (en) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
CN107898756B (zh) * 2017-12-22 2020-11-20 东曜药业有限公司 一种用于皮下或肌肉注射的高浓度尼妥珠单抗制剂及其制备方法和应用
US11873336B2 (en) 2017-12-22 2024-01-16 Teneobio, Inc. Heavy chain antibodies binding to CD22
FI3727423T3 (fi) 2017-12-22 2024-07-04 Novartis Ag Aineenvaihduntahäiriöiden hoito FGF21-varianteilla
AU2019254473A1 (en) * 2018-04-16 2020-12-03 Merck Patent Gmbh Additives for protein formulations to improve thermal stability
EP3560945A1 (en) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
SG11202010977QA (en) * 2018-05-16 2020-12-30 Janssen Biotech Inc Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
CN110732023B (zh) * 2018-07-18 2023-06-16 江苏恒瑞医药股份有限公司 一种her2抗体药物组合物及其用途
KR20200010103A (ko) 2018-07-19 2020-01-30 (주)셀트리온 안정한 액체 약제학적 제제
CA3101069A1 (en) 2018-07-20 2020-01-23 Teneobio, Inc. Heavy chain antibodies binding to cd19
MX2021002764A (es) 2018-09-12 2021-05-12 Silverback Therapeutics Inc Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores.
WO2020060192A1 (ko) * 2018-09-18 2020-03-26 삼성바이오에피스 주식회사 고농도의 계면활성제를 포함하는 트라스투주맙 안정화 액체 제제
EP3870611A1 (en) 2018-10-26 2021-09-01 TeneoBio, Inc. Heavy chain antibodies binding to cd38
WO2020092546A1 (en) * 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
US20210380694A1 (en) * 2018-11-07 2021-12-09 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CN111202845A (zh) * 2018-11-22 2020-05-29 上海医药集团股份有限公司 包含抗cd20抗体的药物配制剂及其制备方法和应用
CN113396158A (zh) 2018-11-26 2021-09-14 诺华股份有限公司 Lpl-gpihbp1融合多肽
EP3906061A4 (en) * 2019-01-04 2023-04-05 Actinium Pharmaceuticals, Inc. METHODS OF TREATMENT OF CANCER USING COMBINATIONS OF PARP INHIBITORS AND ANTIBODY RADIOCONJUGATE
EP3914282A1 (en) 2019-01-25 2021-12-01 Ospedale San Raffaele S.r.l. Inhibitor of dux4 and uses thereof
EP3927729A4 (en) 2019-02-18 2023-10-11 Eli Lilly and Company THERAPEUTIC ANTIBODY FORMULATION
CA3131052A1 (en) * 2019-03-25 2020-10-01 Soon Jae Park Pharmaceutical composition for subcutaneous injection comprising human hyaluronidase ph20 variant and drug
BR112021019334A2 (pt) 2019-04-05 2021-12-07 Teneobio Inc Anticorpos de cadeia pesada que se ligam ao psma
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
EP3983438A1 (en) 2019-06-14 2022-04-20 TeneoBio, Inc. Multispecific heavy chain antibodies binding to cd22 and cd3
CA3141085A1 (en) 2019-06-19 2020-12-24 Brenda Stevens Anti-mesothelin antibodies and immunoconjugates thereof
EP4004050A2 (en) 2019-07-30 2022-06-01 QLSF Biotherapeutics Inc. Multispecific binding compound that bind to lfrrc15 and cd3
US20220281972A1 (en) * 2019-08-07 2022-09-08 Innovent Biologics (Suzhou) Co., Ltd. Formulation comprising anti-pd-1/her2 bispecific antibody, method for preparing same and use thereof
GB201913697D0 (en) 2019-09-23 2019-11-06 King S College London DAP10/DAP12 fusion polypeptides
WO2021079337A1 (en) * 2019-10-23 2021-04-29 Cadila Healthcare Limited Pharmaceutical formulation of anti-her2 antibody and preparation thereof
WO2021097220A1 (en) 2019-11-15 2021-05-20 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
WO2021096278A1 (ko) * 2019-11-15 2021-05-20 삼성바이오에피스 주식회사 항체 의약품용 액상 조성물
EP4073120A2 (en) * 2019-12-09 2022-10-19 Genentech, Inc. Anti-pd-l1 antibody formulations
CU20190104A7 (es) 2019-12-17 2021-08-06 Ct Inmunologia Molecular Formulación estable del anticuerpo nimotuzumab
CN115023441A (zh) 2019-12-18 2022-09-06 特诺福尔股份有限公司 与cd38结合的重链抗体
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
US20230192832A1 (en) * 2020-03-04 2023-06-22 Shanghai Henlius Biotech, Inc. Pharmaceutical formulation comprising bevacizumab
GB202003277D0 (en) 2020-03-06 2020-04-22 King S College London Therapeutic agents
WO2021222578A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
KR20230005179A (ko) 2020-04-29 2023-01-09 테네오바이오, 인코포레이티드 변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
GB202007655D0 (en) 2020-05-22 2020-07-08 King S College London Chimeric nkg2d protein
CN113797161A (zh) * 2020-06-11 2021-12-17 上海宝济药业有限公司 一种重组人透明质酸酶的液体制剂及其应用
CN113827717A (zh) * 2020-06-23 2021-12-24 三生国健药业（上海）股份有限公司 抗her2单克隆抗体冻干制剂及制备方法
PE20230464A1 (es) 2020-06-30 2023-03-14 Teneobio Inc Union de anticuerpos multiespecificos a bcma
WO2022006327A1 (en) 2020-07-01 2022-01-06 Silverback Therapeutics, Inc. Anti-asgr1 antibody conjugates and uses thereof
EP4229094A1 (en) 2020-10-16 2023-08-23 QLSF Biotherapeutics, Inc. Multispecific binding compounds that bind to pd-l1
TW202233684A (zh) 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Preparations containing an antibody against HER2/NEU and their use
JP2024501721A (ja) * 2020-12-30 2024-01-15 上海宝済薬業股▲ふん▼有限公司 組換えヒトヒアルロニダーゼ製剤およびその用途
EP4298128A1 (en) * 2021-02-23 2024-01-03 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Methods of preventing, alleviating or treating tumors
US20240226162A9 (en) 2021-02-25 2024-07-11 Teneobio, Inc. Anti-psma antibodies and car-t structures
CN116917327A (zh) 2021-02-26 2023-10-20 特尼奥生物股份有限公司 抗muc1-c抗体及car-t结构
FI4171622T3 (fi) 2021-03-23 2024-08-01 King S College London Koostumuksia käsittäen nkg2d-, cxcr2- ja dap10/dap12-fuusiopolypeptideja ja niiden käyttömenetelmiä
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
PE20232050A1 (es) 2021-04-06 2023-12-27 Teneobio Inc Anticuerpos anti-cd19 y estructuras car-t
AU2022259688A1 (en) 2021-04-16 2023-10-05 Teneobio, Inc. Anti-cd20 antibodies and car-t structures
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
WO2023004197A1 (en) 2021-07-23 2023-01-26 Teneoten, Inc. Heavy chain antibodies binding to hepatitis b surface antigen
WO2023019556A1 (zh) * 2021-08-20 2023-02-23 齐鲁制药有限公司 一种高浓度抗her2的抗体制剂及其用途
IL312043A (en) 2021-10-14 2024-06-01 Teneobio Inc Mesothelin binding proteins and their uses
WO2024026358A1 (en) 2022-07-27 2024-02-01 Teneobio, Inc. Mesothelin binding proteins and uses thereof
GB202214120D0 (en) 2022-09-27 2022-11-09 King S College London Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.
WO2024178056A1 (en) 2023-02-21 2024-08-29 Teneobio, Inc. C-kit binding proteins, chimeric antigen receptors, and uses thereof
WO2024220256A1 (en) 2023-04-18 2024-10-24 Qlsf Biotherapeutics, Inc. Antibodies binding to ly6g6d

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US533A (en) 1837-12-26 Truss for hermta
US4943A (en) 1847-01-26 Harness-buckle
US2795529A (en) 1954-06-17 1957-06-11 American Home Prod Stabilized hyaluronidase solution containing calcium chloride
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE97498T1 (de) 1984-01-30 1993-12-15 Imp Cancer Res Tech Verbesserungen an wachstumsfaktoren.
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP0491007B1 (en) 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
DE68926248T2 (de) 1989-09-29 1996-12-19 Oncogene Science Inc p100 "neu" menschlisches Protein and Verwendung dieses Proteins zum Nachweis von preneoplasmatischen- oder neoplasmatischen beim Menschen
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US5721348A (en) 1990-12-14 1998-02-24 University Of Connecticut DNA encoding PH-20 proteins
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
JPH08504172A (ja) 1992-06-30 1996-05-07 オンコロジクス，インコーポレイティド 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
DE69428764T2 (de) 1993-12-24 2002-06-20 Merck Patent Gmbh Immunokonjugate
DE69507956T2 (de) 1994-07-21 1999-09-09 Akzo Nobel N.V. Zyklische keton peroxyde zubereitungen
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5573186A (en) 1995-03-20 1996-11-12 Moen Incorporated Stationary venturi diverter valve
ES2332984T3 (es) 1995-03-30 2010-02-16 Pfizer Products Inc. Derivados de quinazolinas.
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
CN102416176A (zh) 1995-07-27 2012-04-18 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
ATE321066T1 (de) 1998-05-06 2006-04-15 Genentech Inc Anti-her2 antikörperzusammensetzung
AT500848B1 (de) 1999-06-25 2008-01-15 Genentech Inc Humanisierte anti-erbb2-antikörper
US6632979B2 (en) * 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
EP2311492B1 (en) 2000-08-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilized preparations
KR100877676B1 (ko) 2000-10-06 2009-01-09 교와 핫꼬 기린 가부시키가이샤 항체 조성물을 생산하는 세포
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DK1324776T4 (en) 2000-10-12 2018-05-28 Genentech Inc CONCENTRATED PROTEIN FORMULATIONS WITH REDUCED VISCOSITY
DE10153197A1 (de) 2001-10-27 2003-05-08 Merck Patent Gmbh Pigment mit Metallglanz
KR20040085185A (ko) 2002-02-14 2004-10-07 추가이 세이야쿠 가부시키가이샤 항체함유 용액제제
TW555245U (en) 2003-01-29 2003-09-21 Hon Hai Prec Ind Co Ltd Cable connector assembly
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
ZA200507978B (en) 2003-03-05 2007-03-28 Halozyme Inc Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
ES2609010T3 (es) 2003-04-04 2017-04-18 Genentech, Inc. Formulaciones de anticuerpos y de proteínas a concentración elevada
CA2525553C (en) 2003-05-14 2011-07-05 Immunogen, Inc. Maytansinoid-antibody conjugate compositions
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
JP2007503435A (ja) 2003-08-26 2007-02-22 ベクトン・ディキンソン・アンド・カンパニー 治療薬の皮内送達法
CA2567520A1 (en) * 2004-06-01 2005-12-15 Genentech, Inc. Maytansinoid-antibody conjugates
KR20100101023A (ko) 2004-07-22 2010-09-15 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
RU2007124933A (ru) 2005-01-28 2009-03-10 Вайет (Us) Стабилизированные жидкие полипептидные составы
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
WO2007024715A2 (en) * 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
MX2008012295A (es) 2006-03-28 2008-10-09 Hoffmann La Roche Formulacion de un anticuerpo monoclonal humano anti-igf-1r.
US20090175847A1 (en) 2007-05-30 2009-07-09 Abbott Laboratories Humanized antibodies to ab (20-42) globulomer and uses thereof
JP5070993B2 (ja) 2007-08-27 2012-11-14 富士通株式会社 音処理装置、位相差補正方法及びコンピュータプログラム
CN101918579A (zh) * 2007-10-22 2010-12-15 先灵公司 完全人抗-vegf抗体和使用方法
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
TWI532498B (zh) * 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
WO2010029054A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Delivery device for use with a therapeutic drug
US7905299B2 (en) 2008-09-18 2011-03-15 Longyear Tm, Inc. Articulation assembly for moving a drill mast
MX2011002402A (es) 2008-09-19 2011-04-05 Hoffmann La Roche Formulacion de anticuerpo novedosa.
US20100305500A1 (en) 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
NZ598518A (en) 2009-08-04 2014-12-24 Genentech Inc Concentrated polypeptide formulations with reduced viscosity
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
RU2013126477A (ru) 2010-11-08 2014-12-20 Дженентек, Инк. Вводимые подкожно антитела против рецептора il-6

Also Published As

Publication number Publication date
EA201200204A1 (ru) 2012-08-30
US20130216532A1 (en) 2013-08-22
IL217382A0 (en) 2012-02-29
JP5878144B2 (ja) 2016-03-08
PL2459167T3 (pl) 2013-10-31
CN102573789A (zh) 2012-07-11
CA2768458A1 (en) 2011-02-03
EP4257150A2 (en) 2023-10-11
JP2013224305A (ja) 2013-10-31
PL2687202T3 (pl) 2023-07-24
KR20130041374A (ko) 2013-04-24
AU2010277657B2 (en) 2013-05-02
TW201328708A (zh) 2013-07-16
SI2459167T2 (sl) 2022-05-31
EP2687202A1 (en) 2014-01-22
RS52913B (en) 2014-02-28
ECSP23041058A (es) 2023-07-31
DOP2015000255A (es) 2016-01-31
LT2687202T (lt) 2023-07-10
CY1114185T1 (el) 2016-08-31
EA027553B1 (ru) 2017-08-31
SG178185A1 (en) 2012-03-29
ES2413090T5 (es) 2022-05-03
EP4257150A3 (en) 2023-11-01
DK2687202T3 (da) 2023-07-10
WO2011012637A3 (en) 2011-08-25
WO2011012637A4 (en) 2011-11-03
AU2010277657A1 (en) 2012-02-02
MX2012001124A (es) 2012-03-29
SI2459167T1 (sl) 2013-07-31
CL2013002550A1 (es) 2013-12-13
EA031013B1 (ru) 2018-11-30
CN113967194A (zh) 2022-01-25
HK1215157A1 (zh) 2016-08-19
MX355450B (es) 2018-04-18
TWI401089B (zh) 2013-07-11
MA33471B1 (fr) 2012-07-03
HUE062122T2 (hu) 2023-09-28
ZA201207815B (en) 2013-07-31
PL2459167T5 (pl) 2023-12-11
RS52913B2 (sr) 2022-05-31
ECSP12011643A (es) 2012-02-29
ZA201109459B (en) 2013-05-29
NZ603900A (en) 2014-03-28
KR101769652B1 (ko) 2017-08-18
DK2459167T3 (da) 2013-06-03
ES2948033T3 (es) 2023-08-30
HRP20230462T1 (hr) 2023-07-21
IN2012CN00961A (es) 2013-05-24
IL253941B (en) 2021-10-31
CN102573789B (zh) 2015-09-30
US9968676B2 (en) 2018-05-15
WO2011012637A2 (en) 2011-02-03
US20210353753A1 (en) 2021-11-18
US20110044977A1 (en) 2011-02-24
CL2012000269A1 (es) 2012-10-12
IL217382A (en) 2017-09-28
KR101413947B1 (ko) 2014-06-30
PE20120665A1 (es) 2012-06-01
SI2687202T1 (sl) 2023-07-31
US9345661B2 (en) 2016-05-24
TN2012000023A1 (en) 2013-09-19
EA201400270A1 (ru) 2014-06-30
SG193146A1 (en) 2013-09-30
PT2459167E (pt) 2013-06-24
GT201200024A (es) 2013-10-28
EP2459167B2 (en) 2022-03-02
JP2013500947A (ja) 2013-01-10
MY163001A (en) 2017-07-31
HRP20130697T1 (en) 2013-09-30
TW201106973A (en) 2011-03-01
TWI474834B (zh) 2015-03-01
FI2687202T3 (fi) 2023-06-21
US20180228895A1 (en) 2018-08-16
EP4339212A2 (en) 2024-03-20
CA2768458C (en) 2013-12-03
BR112012002080A2 (pt) 2016-04-12
EP2459167A2 (en) 2012-06-06
JP5462944B2 (ja) 2014-04-02
CN105168125A (zh) 2015-12-23
CO6430421A2 (es) 2012-04-30
CR20110679A (es) 2012-03-06
RS64314B1 (sr) 2023-08-31
AR108936A2 (es) 2018-10-10
EP2687202B1 (en) 2023-05-10
UA102166C2 (ru) 2013-06-10
NZ597190A (en) 2012-12-21
US20160166689A1 (en) 2016-06-16
PT2687202T (pt) 2023-06-15
UA104254C2 (ru) 2014-01-10
ES2413090T3 (es) 2013-07-15
EP2459167B1 (en) 2013-05-15
AR077605A1 (es) 2011-09-07
US20240207400A1 (en) 2024-06-27
MY172245A (en) 2019-11-19
HRP20130697T4 (hr) 2022-04-29
KR20120038540A (ko) 2012-04-23
HK1172236A1 (en) 2013-04-19
EP4339212A3 (en) 2024-06-19
IL253941A0 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
PE20131324A1 (es) Formulacion subcutanea de anticuerpo anti-her2
RS54769B1 (sr) Visoko koncentrovane farmaceutske formulacije koje sadrže anti-cd20 antitelo
AR122746A2 (es) Una formulación farmacéutica líquida estable de anticuerpo
CL2017002488A1 (es) Formulación farmacéutica estable para administración intratecal que comprende una proteína arilsulfatasa a (asa), sal y un tensoactivo de polisorbato y/o un agente amortiguador, y que además puede contener un agente estabilizante; contenedor que comprende dicha formulación; uso para tratar la enfermedad leucodistrofia metacrómatica (mld). (divisional solicitud 3654-2012)
PE20091852A1 (es) Formulacion farmaceutica que comprende un anticuerpo de ox40l
PE20110302A1 (es) Formulacion farmaceutica de un anticuerpo contra p-selectina
AR107014A1 (es) Formulación farmacéutica acuosa
AR067011A1 (es) Formulaciones de anticuerpos
PE20131166A1 (es) Formulacion de premezcla de dexmedetomidina
PE20181365A1 (es) Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos
IN2014CN02592A (es)
PE20230169A1 (es) Suministro al sistema nervioso central de agentes terapeuticos
IN2015MU00865A (es)
PE20181790A1 (es) Metodos para tratar o prevenir trastornos relacionados con el colesterol
EA201492021A1 (ru) Антительный состав
PE20091328A1 (es) Formulacion de anticuerpo
PE20140166A1 (es) Composicion farmaceutica que comprende deferasirox
CL2019001366A1 (es) Formulaciones tamponadas exendina (9-39).
BR112021017890A2 (pt) Composição líquida compreendendo um anticorpo do receptor alfa de interleucina-4 humana
AR090244A1 (es) Formulacion de anticuerpo anti-selectina p
CL2011000614A1 (es) Forma de dosificacion oral solida que comprende alisquireno solo o en combinacion con otro agente activo; proceso de preparacion; y uso en el tratamiento de enfermedades tales comohipertension, angina, ateroesclerosis, entre otras.
AR124100A2 (es) Composiciones farmacéuticas para la administración intratecal de enzimas lisosómicas
TH151334A (th) สูตรผสมเชิงเภสัชกรรมที่เข้มข้นสูง, ซึ่งเสถียรของแอนติ-CD20 แอนติบอดี (anti-CD20 antibody)
TH138064A (th) สูตรตำรับแอนทิบอดีแอนทิ-her2 ใต้หนัง

Legal Events

Date Code Title Description
FG Grant, registration